<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007317</url>
  </required_header>
  <id_info>
    <org_study_id>OS-BCC-P2-01</org_study_id>
    <nct_id>NCT02007317</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study</brief_title>
  <official_title>A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oshadi Drug Administration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oshadi Drug Administration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is single-arm, none randomized, open label, two-dose-cohorts, single center&#xD;
      clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients&#xD;
      with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned&#xD;
      surgical excision of the lesion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and serious adverse events occurence</measure>
    <time_frame>treatment end (day 60 or 90)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The primary efficacy endpoint of this study is Overall Response Rate (ORR)</measure>
    <time_frame>treatment end (day 60 or 90)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To estimate the duration of treatment to achieve response</measure>
    <time_frame>9 months</time_frame>
    <description>To estimate the duration of treatment needed to achieve response</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>BCC</condition>
  <arm_group>
    <arm_group_label>Oshadi D and Oshadi R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti tumor agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oshadi D &amp; Oshadi R</intervention_name>
    <description>Anti tumor agents</description>
    <arm_group_label>Oshadi D and Oshadi R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 21 years old with tissue confirmed diagnosis of local BCC.&#xD;
&#xD;
          -  Patient is candidate for surgical excision of the BCC in few months.&#xD;
&#xD;
          -  BCC lesion ≥10mm in its longest diameter.&#xD;
&#xD;
          -  Sexually active fertile patients and their partners must agree to use medically&#xD;
             accepted methods of contraception during therapy and 3 months after the last dose of&#xD;
             the study drugs.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative pregnancy test at&#xD;
             screening.&#xD;
&#xD;
          -  Patient must understand and be willing to give written informed consent prior to any&#xD;
             study procedures or evaluations and be willing to adhere to all study schedules and&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled Intercurrent illness or any history of significant cardiac, renal,&#xD;
             neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic&#xD;
             hepatic disease or any other disease which in the judgment of the investigator would&#xD;
             interfere with the study or confound the results.&#xD;
&#xD;
          -  Other active cancer disease.&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dL for males and &gt;1.4 mg/dL for females.&#xD;
&#xD;
          -  Female patient who are breastfeeding or have a positive pregnancy test at screening or&#xD;
             at any time during the study.&#xD;
&#xD;
          -  Any acute cardiovascular event during the last 6 months prior to inclusion.&#xD;
&#xD;
          -  Symptomatic congestive heart failure with ejection fraction &lt; 30%.&#xD;
&#xD;
          -  Patient has prothrombin time/International Normalization Ration (PT/INR) or partial&#xD;
             thromboplastin time (PTT) test results &gt; 1.3 UNL.&#xD;
&#xD;
          -  Hemoglobin ≤ 11 g/dL&#xD;
&#xD;
          -  Platelets &lt; 150,000 per microliter&#xD;
&#xD;
          -  White blood cell count&lt;3,000 x109/L and/or absolute neutrophils count &lt;1.5 x 109/L&#xD;
&#xD;
          -  Significant swallowing disorders.&#xD;
&#xD;
          -  History of small bowel surgery.&#xD;
&#xD;
          -  Any history of pelvic or abdominal radiation.&#xD;
&#xD;
          -  Pre-existing mal-absorption syndrome, irritable bowel syndrome or other clinical&#xD;
             situation which could affect oral absorption.&#xD;
&#xD;
          -  Mental disorders.&#xD;
&#xD;
          -  Inability to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Heller, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofeh Medical Center, Zrifin, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

